当前位置:首页 - 行情中心 - 广康生化(300804) - 财务分析 - 利润表

广康生化

(300804)

  

流通市值:9.50亿  总市值:25.57亿
流通股本:2750.00万   总股本:7400.00万

利润表

报告期2026-09-302026-06-302026-03-312025-12-31
公司类型通用通用通用通用
一、营业总收入509,385,229.18382,211,123.05160,416,302.71754,799,505.24
  营业收入509,385,229.18382,211,123.05160,416,302.71754,799,505.24
二、营业总成本529,376,132.43378,926,709.86162,627,495.93713,052,217.39
  营业成本412,772,593.84301,840,571.96129,645,247.42572,564,464.1
  税金及附加1,788,724.591,171,762.1583,703.182,153,297.78
  销售费用14,240,921.789,367,934.633,706,152.9517,468,195.95
  管理费用57,354,267.3337,856,284.5215,382,921.4368,012,945.88
  研发费用25,560,532.1617,607,732.18,334,771.3834,505,761.1
  财务费用17,659,092.7311,082,424.554,974,699.5718,347,552.58
  其中:利息费用8,126,135.634,962,631.812,226,120.1910,589,262.44
  其中:利息收入841,370.23668,492.69295,342.76786,262.18
三、其他经营收益
  加:公允价值变动收益89,87181,351-289,556.61
  加:投资收益4,111,443.81,656,990.041,335,783.916,368,040.75
  资产处置收益00--15,128.49
  资产减值损失(新)----3,024,871.73
  信用减值损失(新)-2,272,536.27-2,764,755.85-437,237.93740,924.76
  其他收益978,804.57557,795.27264,796.211,118,020.39
四、营业利润-17,083,320.152,815,793.65-1,047,851.0347,223,830.14
  加:营业外收入142,651.9536,637.6532,437.651,299,217.7
  减:营业外支出2,142,188.651,742,056.68695,501.265,936,988.05
五、利润总额-19,082,856.851,110,374.62-1,710,914.6442,586,059.79
  减:所得税费用-7,684,232.07-3,099,599.88-1,328,155.272,168,158.56
六、净利润-11,398,624.784,209,974.5-382,759.3740,417,901.23
(一)按经营持续性分类
  持续经营净利润-11,398,624.784,209,974.5-382,759.3740,417,901.23
(二)按所有权归属分类
  归属于母公司股东的净利润-12,106,729.93,306,742.02-575,458.9940,713,344.1
  少数股东损益708,105.12903,232.48192,699.62-295,442.87
  扣除非经常损益后的净利润-16,192,687.382,804,241.55-1,374,818.8438,064,759.45
七、每股收益
  (一)基本每股收益-0.160.04-0.010.55
  (二)稀释每股收益-0.160.04-0.010.55
八、其他综合收益-1,761.3-1,017.57--
  归属于母公司股东的其他综合收益-1,761.3-1,017.57--
九、综合收益总额-11,400,386.084,208,956.93-382,759.3740,417,901.23
  归属于母公司股东的综合收益总额-12,108,491.23,305,724.45-575,458.9940,713,344.1
  归属于少数股东的综合收益总额708,105.12903,232.48192,699.62-295,442.87
公告日期2026-10-242026-08-282026-04-242026-04-24
审计意见(境内)标准无保留意见
TOP↑